Download to heal: navigating the pixelated path of digital therapeutics in psychiatric care

Digital therapeutics have evolved rapidly with technological advances in healthcare. Despite their increasing use, gaps remain in understanding their regulatory frameworks, integration, and efficacy for conditions like substance use disorder, insomnia, attention deficit hyperactivity disorder, and posttraumatic stress disorder. This study evaluates U.S. Food and Drug Administration (FDA)-approved digital therapeutics and explores their potential to revolutionize psychiatric treatments amid ongoing technological and regulatory changes. We conducted a comprehensive review of major databases, focusing on articles published until January 2024 about FDA-approved digital therapeutics. We excluded non-English articles, those lacking empirical data, and those focusing on non-FDA-approved therapeutics. Our analysis covered regulatory compliance, clinical outcomes, and integration with traditional treatments. A review of nine FDA-cleared digital therapeutics revealed benefits, such as improved treatment accessibility and potential reductions in healthcare costs. For example, through Somryst, a cognitive-behavioral therapy-based treatment for insomnia, over 40% of users overcame chronic insomnia, and 60% experienced improvements without adverse effects. However, challenges remain, including low provider adoption, inadequate insurance coverage, and high user dropout rates. While digital therapeutics enhance accessibility, they face regulatory challenges, reimbursement issues, and require robust clinical evidence. Success depends on collaboration among stakeholders to demonstrate value, ensure safety, and integrate them into existing healthcare systems.